
Marijuana Company of America, Inc., together with its subsidiaries, develops, produces, and distributes cannabis and cannabidiol (CBD) products under the hempSMART brand name in the United States. The company offers hempSMART products comprising hempSMART Brain, a patented and formulated personal care consumer product for brain wellness; hempSMART Pain capsules for temporary relief of minor discomfort with physical activity; hempSMART Pain Cream to reduce minor discomfort and promote muscle relaxation; hempSMART Drops, a hemp CBD oil tincture drops; hempSMART Pet Drops for cats and dogs; hempSMART Face, a facial moisturizer; and hempSMART drink mix, an industrial hemp based powderized CBD drink through its web site and affiliate marketing programs. It also distributes hemp and CBD products, such as smoke and vape shop related products to wholesalers, c-stores, specialty retailers, and consumers through www.cdistro.com. The company was formerly known as Converge Global, Inc. and changed its name to Marijuana Company of America, Inc. in December 2015. Marijuana Company of America, Inc. was incorporated in 1985 and is based in Los Angeles, California.
Marijuana Company of America, Inc. trades as MCOA on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.
The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.
Latest available fiscal data shows $990,290 of revenue and -$14.27M of net income.
Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.
The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.
Marijuana Company of America, Inc. can be compared against peers such as Craftport Cannabis Corp., CannaPharmaRX, Inc., Isracann Biosciences Inc., ManifestSeven Holdings Corporation, North Bud Farms Inc., Resilient Healthcare Corp.
A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.
Current signals to investigate include market capitalization of $2.21M, beta of 8.29, and return on equity of +160.1%.
This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.
Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.
MCOA currently shows total debt of $5.08M and beta of 8.29. Missing data should be treated as a research gap, not as low risk.
Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.
No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.
Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.
No recent SEC-style filings are available for this symbol yet.
Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.
Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.
Company website: https://www.marijuanacompanyofamerica.com
For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.